This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Bezafibrate Infarction Prevention Study

Authoring team

  • double-blind, placebo-controlled trial
    • 3,090 patients with coronary heart disease (CHD) aged < 74 years (2,825 men, 265 women)
    • on entry total cholesterol 4.7 mmol/L-6.5mmol/L, triglyceride <3.4 mmol/L, HDL-c <1.16 mmol/L
    • treatment - bezafibrate 400mg per day or placebo
    • mean follow-up 6.2 years
  • no significant effect of bezafibrate on combined incidence of non-fatal MI or death from CHD 
    • post-hoc subgroup analysis indicated the possibility of a substantially greater benefit of bezafibrate in the subset of patients with a baseline plasma triglyceride > 2.25 mmol/L - in this subgroup event rate was 12.0% in the bezafibrate group and 19.7% in the placebo group (relative reduction of 39% (p=0.02))

Reference:

  1. Circulation. 2000 Jul 4;102(1):21-7.
  2. The British Journal of Diabetes and Vascular Disease 2003; 3(3): 162-7.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.